Cabozantinib and immunotherapy for advanced stomach or bowel cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- Your daily functioning is good (ECOG 0–1)
- You have confirmed stomach/gastroesophageal/esophagus/colon cancer or liver cancer (hepatocellular carcinoma)
- Your cancer is stage 3 that can’t be fully removed or is stage 4, and you have measurable tumor on scans
- You can have required tumor biopsies for study testing (before treatment, and sometimes again later)
- If you have stomach/GEJ/esophagus cancer, you must have tried at least one standard treatment and your cancer got worse or you couldn’t tolerate it
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This study tests the drug cabozantinib (a pill that stops cancer growth) for people whose liver cancer has progressed after standard first-line immunotherapy. The goal is to see if it can slow down or shrink the cancer.
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.